Search clinical trials for: 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine

Total 11 results

U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Meningitis, Meningococcal, Serogroup B

United States
U.S. Army Medical Research and Development Command

Completed

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine (HOPS)

Meningococcal Infection, Group B

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Invasive Meningococcal Disease

United States, Poland
Novartis Vaccines

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Meningococcal Disease

United Kingdom
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Infections, Meningococcal

Mexico, Argentina
GlaxoSmithKline

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Infections, Meningococcal

Chile, Canada, Australia
Novartis Vaccines

Completed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Meningococcal Disease | Meningococcal Meningitis

Spain, Italy, United Kingdom, Czech Republic
Novartis

Completed

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Meningitis, Meningococcal, Serogroup B

Poland
Novartis Vaccines
Novartis

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Meningococcal Disease

Korea, Republic of
GlaxoSmithKline

Active, not recruiting

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Infections, Meningococcal

United States, Italy
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Infections, Meningococcal

United States, Puerto Rico

3

Subscribe